Envestnet Asset Management Inc. Purchases 189,877 Shares of IDEAYA Biosciences, Inc. $IDYA

Envestnet Asset Management Inc. lifted its holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 174.0% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 299,032 shares of the company’s stock after acquiring an additional 189,877 shares during the period. Envestnet Asset Management Inc.’s holdings in IDEAYA Biosciences were worth $8,137,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Geode Capital Management LLC grew its stake in IDEAYA Biosciences by 1.6% during the second quarter. Geode Capital Management LLC now owns 2,113,164 shares of the company’s stock worth $44,424,000 after purchasing an additional 33,286 shares during the period. Fiera Capital Corp boosted its holdings in shares of IDEAYA Biosciences by 26.6% during the 2nd quarter. Fiera Capital Corp now owns 1,532,269 shares of the company’s stock worth $32,208,000 after buying an additional 322,404 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in shares of IDEAYA Biosciences by 4.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,238,094 shares of the company’s stock worth $26,025,000 after buying an additional 50,000 shares during the period. Ensign Peak Advisors Inc grew its position in shares of IDEAYA Biosciences by 126.4% during the 2nd quarter. Ensign Peak Advisors Inc now owns 741,833 shares of the company’s stock worth $15,593,000 after buying an additional 414,189 shares during the period. Finally, Millennium Management LLC increased its stake in shares of IDEAYA Biosciences by 345.2% in the 1st quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock valued at $8,970,000 after acquiring an additional 424,625 shares in the last quarter. Institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

IDYA opened at $32.90 on Friday. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $39.28. The firm has a market capitalization of $2.89 billion, a PE ratio of -25.11 and a beta of 0.10. The company’s 50-day moving average is $34.23 and its 200 day moving average is $30.46.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings data on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, topping analysts’ consensus estimates of ($1.03) by $0.09. The company had revenue of $21.75 million for the quarter, compared to the consensus estimate of $5.95 million. The business’s revenue for the quarter was up 55.7% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.49) earnings per share. As a group, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

Analyst Upgrades and Downgrades

IDYA has been the subject of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Thursday, January 22nd. JPMorgan Chase & Co. increased their price objective on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Wall Street Zen upgraded IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 9th. Mizuho upped their price target on IDEAYA Biosciences from $44.00 to $46.00 and gave the stock an “outperform” rating in a research note on Tuesday, November 11th. Finally, Wedbush increased their price target on IDEAYA Biosciences from $49.00 to $52.00 and gave the stock an “outperform” rating in a report on Wednesday. Fifteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $48.69.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.